Comparison of a portable, pneumotach flow-sensor-based spirometer (Spirofy™) with the vitalograph alpha Touch™ spirometer in evaluating lung function in healthy individuals, asthmatics, and COPD patients-a randomized, crossover study

Spirofy™ is India's first portable, pneumotach flow-sensor-based digital spirometer developed to diagnose asthma and chronic obstructive pulmonary disease (COPD). In this study, we compared the performance of the Spirofy™ device with that of the Vitalograph Alpha Touch™ spirometer in measuring...

Full description

Saved in:
Bibliographic Details
Published in:BMC pulmonary medicine 2024-05, Vol.24 (1), p.230-230, Article 230
Main Authors: Talwar, Deepak, Balamurugan, S, Modi, Mahavir, Salvi, Sundeep, Lopez, Meena, Shah, Rushika, Vaidya, Abhijit, Barne, Monica, Madas, Sapna, Kulkarni, Nandan, Sawant, Sandesh, Gogtay, Jaideep
Format: Article
Language:English
Subjects:
Adult
Aged
Asthma
Asthma - diagnosis
Asthma - physiopathology
Asthmatics
Chronic obstructive pulmonary disease
Clinical trials
Comparative analysis
Cross-Over Studies
Diagnosis
Female
Forced Expiratory Volume
Forced vital capacity
Humans
India
Lung diseases
Lung diseases, Obstructive
Male
Medical equipment
Medical research
Medicine, Experimental
Middle Aged
Primary care
Pulmonary Disease, Chronic Obstructive - diagnosis
Pulmonary Disease, Chronic Obstructive - physiopathology
Respiratory diseases
Respiratory function
Sensors
Severe acute respiratory syndrome coronavirus 2
Spirometer
Spirometry
Spirometry - instrumentation
Tactile stimuli
Vital Capacity
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Spirofy™ is India's first portable, pneumotach flow-sensor-based digital spirometer developed to diagnose asthma and chronic obstructive pulmonary disease (COPD). In this study, we compared the performance of the Spirofy™ device with that of the Vitalograph Alpha Touch™ spirometer in measuring the lung capacities of healthy individuals, asthmatics, and COPD patients. We also assessed the inter-device variability between two Spirofy™ devices. In a randomized, three-way crossover, open-label study, we measured the differences in forced expiratory volume in the first second (FEV ) and forced vital capacity (FVC) between the Spirofy™ and Vitalograph Alpha Touch™ spirometers. A proportion of the FEV /FVC ratio distribution of
ISSN:1471-2466
1471-2466
DOI:10.1186/s12890-024-02972-4